Year: 2025
Type: article
Study design: Observational Study
Abstract: PURPOSE: Duration of treatment for uncomplicated enterococcal bacteremia is unknown. This study aims to evaluate the clinical outcomes of patients treated with short courses (4-10 days) compared to those receiving longer regimens (11-18 days). METHODS: This retrospective study was conducted at the Lausanne University Hospital, Switzerland (January 2015-June 2024) and included adult patients with uncomplicated enterococcal bacteremia. Primary outcome was a composite of mortality, recurrence of bacteremia by the same enterococcal species and development of bone and joint infection within 120 days. RESULTS: During the study period, 331 episodes of uncomplicated enterococcal bacteremia were included. The median duration of antimicrobial treatment was 12 days (interquartile range: 8-15); 138 (42%) and 193 (58%) episodes received a short (4-10 days) and long (11-18 days) duration of antimicrobial treatment, respectively. The primary endpoint was observed in 77 (23%) episodes; 120-day mortality was 21% (69 episodes), recurrence of bacteremia was 4% (12 episodes), and bone and joint infection was 0.6% (2 episodes). No difference in primary endpoint was observed between episodes receiving short and long courses of antimicrobial treatment (23% versus 23%; P = 1.000). The Cox multivariable regression model found that malignancy (aHR 2.00, 95% CI 1.24-3.22), immunosuppression (1.78, 1.09-2.90), cirrhosis (2.53, 1.42-4.51), and sepsis or septic shock (2.48, 1.52-4.03) were associated with primary endpoint; a short course of antimicrobial treatment was not associated with primary endpoint (1.03, 0.65-1.62). CONCLUSION: Among uncomplicated enterococcal bacteremia giving a short duration of antimicrobial treatment is reasonable.
Language: English
Subfield: Molecular Medicine
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $2,890
Funder: Université de Lausanne
OpenAlex ID: W4415994818